Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             28 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases André, F.

35 12 p. 1169-1180
artikel
2 A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse Blay, J.-Y.

35 12 p. 1157-1168
artikel
3 Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come Blay, J.-Y.

35 12 p. 1207-1208
artikel
4 Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF V600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial Ciardiello, D.

35 12 p. 1105-1115
artikel
5 Corrigendum to “60P Hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: A phase II trial” [Annals of Oncology 33 (2023) S568] Wang, X.

35 12 p. 1209
artikel
6 Does total neoadjuvant therapy improve overall survival in rectal cancer? Interpretation of the PRODIGE-23 and other studies Socha, J.

35 12 p. 1204-1205
artikel
7 Duration of adjuvant imatinib treatment in GIST at high risk of relapse Akkus, E.

35 12 p. 1205-1206
artikel
8 Editorial Board
35 12 p. iii
artikel
9 Elusive biomarkers of sensitivity to combined PD1/CTLA4 blockade in metastatic castration-resistant prostate cancer Antonarakis, E.S.

35 12 p. 1077-1079
artikel
10 First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration ☆ Rodon, J.

35 12 p. 1138-1147
artikel
11 Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial Toh, H.C.

35 12 p. 1181-1190
artikel
12 How AI will transform cancer care ☆ Kather, J.N.

35 12 p. 1085-1087
artikel
13 Inoperable stage III EGFR mutant non-small-cell lung cancer: time for drug first, local later? John, A.

35 12 p. 1074-1076
artikel
14 Investigating the ‘liquid–solid interface’ in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatment—where do we draw the line? Beehuat Tan, I.

35 12 p. 1067-1070
artikel
15 Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial ☆ van Wilpe, S.

35 12 p. 1126-1137
artikel
16 Is adjuvant ribociclib ready for prime time? Natarajan, A.

35 12 p. 1200-1201
artikel
17 Long-term adjuvant therapy for high-risk GIST: towards tailored imatinib duration? Nishida, T.

35 12 p. 1083-1084
artikel
18 Lung cancer research and treatment: global perspectives and strategic calls to action Meyer, M.-L.

35 12 p. 1088-1104
artikel
19 Odronextamab against relapsed or refractory follicular lymphoma Shimazu, Y.

35 12 p. 1208
artikel
20 Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study ☆ Lu, S.

35 12 p. 1116-1125
artikel
21 Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study Long, G.V.

35 12 p. 1191-1199
artikel
22 Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma ☆ Agarwal, N.

35 12 p. 1148-1156
artikel
23 Reply to the manuscript ‘A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse’ by J.-Y. Blay et al. Petrelli, F.

35 12 p. 1206-1207
artikel
24 Response to letters to the Editor on ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ Goetz, M.P.

35 12 p. 1202-1204
artikel
25 Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway Boscolo Bielo, L.

35 12 p. 1080-1082
artikel
26 Table of Contents
35 12 p. i-ii
artikel
27 The global epidemic of early-onset cancer: nature, nurture, or both? ☆ Ogino, S.

35 12 p. 1071-1073
artikel
28 Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al De Sanctis, R.

35 12 p. 1201-1202
artikel
                             28 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland